China FDA Expands Clinical Data Witch Hunt To CROs, Study Sites
This article was originally published in PharmAsia News
Drug manufacturers in China were firstly required to conduct self-audits of the clinical data submitted to support their product approval applications, then clinical sites were asked to improve study oversight. Now, contract research organizations seem to have become the latest target as the China FDA expands a crackdown on clinical data forgery in which it seemingly considers a 20% failure rate not sufficient.
You may also be interested in...
China has shown willingness to go tit-for-tat in its bilateral disputes with the US and the latest comments from US officials show an underlying distrust over clinical data and vaccines safety in China, raising fresh concerns just when collaboration is needed to accelerate availability of the first vaccines in the global pandemic.
As the largest manufacturer of active pharmaceutical ingredients globally, China is bracing for more uncertainty amid the global pandemic and fast-changing environment, particularly in the US.
Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.